vs
AMERICAN SHARED HOSPITAL SERVICES（AMS）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是AMERICAN SHARED HOSPITAL SERVICES的113.7倍（$878.4M vs $7.7M）。AMERICAN SHARED HOSPITAL SERVICES净利率更高（-8.2% vs -9.8%，领先1.6%）。EXACT SCIENCES CORP同比增速更快（23.1% vs -14.8%）。EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-2.7M）。过去两年AMERICAN SHARED HOSPITAL SERVICES的营收复合增速更高（21.7% vs 17.4%）
美国共享医院服务公司为医疗机构提供放射治疗、立体定向放射外科及诊断成像设备的整体外包解决方案，免除医院高昂的前期资本投入，主要业务覆盖北美，同时服务拉美及部分亚太地区的公立、私立医院客户。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
AMS vs EXAS — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $7.7M | $878.4M |
| 净利润 | $-631.0K | $-86.0M |
| 毛利率 | 11.7% | 70.1% |
| 营业利润率 | -18.1% | -9.4% |
| 净利率 | -8.2% | -9.8% |
| 营收同比 | -14.8% | 23.1% |
| 净利润同比 | 52.5% | 90.1% |
| 每股收益（稀释后） | $-0.09 | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $7.7M | $878.4M | ||
| Q3 25 | $7.2M | $850.7M | ||
| Q2 25 | $7.1M | $811.1M | ||
| Q1 25 | $6.1M | $706.8M | ||
| Q4 24 | $9.1M | $713.4M | ||
| Q3 24 | $7.0M | $708.7M | ||
| Q2 24 | $7.1M | $699.3M | ||
| Q1 24 | $5.2M | $637.5M |
| Q4 25 | $-631.0K | $-86.0M | ||
| Q3 25 | $-17.0K | $-19.6M | ||
| Q2 25 | $-280.0K | $-1.2M | ||
| Q1 25 | $-625.0K | $-101.2M | ||
| Q4 24 | $-1.3M | $-864.6M | ||
| Q3 24 | $-207.0K | $-38.2M | ||
| Q2 24 | $3.6M | $-15.8M | ||
| Q1 24 | $119.0K | $-110.2M |
| Q4 25 | 11.7% | 70.1% | ||
| Q3 25 | 22.1% | 68.6% | ||
| Q2 25 | 23.1% | 69.3% | ||
| Q1 25 | 15.4% | 70.8% | ||
| Q4 24 | 35.3% | 69.0% | ||
| Q3 24 | 19.6% | 69.4% | ||
| Q2 24 | 35.0% | 69.8% | ||
| Q1 24 | 41.1% | 70.0% |
| Q4 25 | -18.1% | -9.4% | ||
| Q3 25 | -4.8% | -3.0% | ||
| Q2 25 | -7.7% | -0.3% | ||
| Q1 25 | -21.3% | -13.6% | ||
| Q4 24 | -20.2% | -122.8% | ||
| Q3 24 | -12.7% | -5.6% | ||
| Q2 24 | -0.0% | -3.8% | ||
| Q1 24 | -1.6% | -16.7% |
| Q4 25 | -8.2% | -9.8% | ||
| Q3 25 | -0.2% | -2.3% | ||
| Q2 25 | -4.0% | -0.1% | ||
| Q1 25 | -10.2% | -14.3% | ||
| Q4 24 | -14.6% | -121.2% | ||
| Q3 24 | -3.0% | -5.4% | ||
| Q2 24 | 51.0% | -2.3% | ||
| Q1 24 | 2.3% | -17.3% |
| Q4 25 | $-0.09 | $-0.45 | ||
| Q3 25 | $0.00 | $-0.10 | ||
| Q2 25 | $-0.04 | $-0.01 | ||
| Q1 25 | $-0.10 | $-0.54 | ||
| Q4 24 | $-0.21 | $-4.69 | ||
| Q3 24 | $-0.03 | $-0.21 | ||
| Q2 24 | $0.55 | $-0.09 | ||
| Q1 24 | $0.02 | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5M | $964.7M |
| 总债务越低越好 | $17.4M | — |
| 股东权益账面价值 | $24.0M | $2.4B |
| 总资产 | $55.5M | $5.9B |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势，按日历期对齐
| Q4 25 | $3.5M | $964.7M | ||
| Q3 25 | $5.1M | $1.0B | ||
| Q2 25 | $11.1M | $858.4M | ||
| Q1 25 | $11.2M | $786.2M | ||
| Q4 24 | $11.0M | $1.0B | ||
| Q3 24 | $13.8M | $1.0B | ||
| Q2 24 | $14.2M | $946.8M | ||
| Q1 24 | $12.8M | $652.1M |
| Q4 25 | $17.4M | — | ||
| Q3 25 | $18.2M | — | ||
| Q2 25 | $19.1M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | $20.4M | — | ||
| Q3 24 | $14.4M | — | ||
| Q2 24 | $15.1M | — | ||
| Q1 24 | $15.6M | — |
| Q4 25 | $24.0M | $2.4B | ||
| Q3 25 | $24.6M | $2.5B | ||
| Q2 25 | $24.5M | $2.5B | ||
| Q1 25 | $24.6M | $2.4B | ||
| Q4 24 | $25.2M | $2.4B | ||
| Q3 24 | $26.4M | $3.2B | ||
| Q2 24 | $26.5M | $3.2B | ||
| Q1 24 | $22.8M | $3.1B |
| Q4 25 | $55.5M | $5.9B | ||
| Q3 25 | $59.6M | $5.9B | ||
| Q2 25 | $63.5M | $5.8B | ||
| Q1 25 | $63.3M | $5.7B | ||
| Q4 24 | $60.2M | $5.9B | ||
| Q3 24 | $63.3M | $6.7B | ||
| Q2 24 | $60.8M | $6.7B | ||
| Q1 24 | $50.1M | $6.4B |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 0.81× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-704.0K | $151.7M |
| 自由现金流经营现金流 - 资本支出 | $-2.7M | $120.4M |
| 自由现金流率自由现金流/营收 | -34.8% | 13.7% |
| 资本支出强度资本支出/营收 | 25.7% | 3.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.5M | $356.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-704.0K | $151.7M | ||
| Q3 25 | $1.7M | $219.9M | ||
| Q2 25 | $-372.0K | $89.0M | ||
| Q1 25 | $2.5M | $30.8M | ||
| Q4 24 | $274.0K | $47.1M | ||
| Q3 24 | $472.0K | $138.7M | ||
| Q2 24 | $1.3M | $107.1M | ||
| Q1 24 | $-1.9M | $-82.3M |
| Q4 25 | $-2.7M | $120.4M | ||
| Q3 25 | $-2.0M | $190.0M | ||
| Q2 25 | $-2.3M | $46.7M | ||
| Q1 25 | $-1.5M | $-365.0K | ||
| Q4 24 | $-4.4M | $10.7M | ||
| Q3 24 | $-407.0K | $112.6M | ||
| Q2 24 | $70.0K | $71.2M | ||
| Q1 24 | $-3.0M | $-120.0M |
| Q4 25 | -34.8% | 13.7% | ||
| Q3 25 | -28.3% | 22.3% | ||
| Q2 25 | -32.1% | 5.8% | ||
| Q1 25 | -24.7% | -0.1% | ||
| Q4 24 | -48.4% | 1.5% | ||
| Q3 24 | -5.8% | 15.9% | ||
| Q2 24 | 1.0% | 10.2% | ||
| Q1 24 | -58.4% | -18.8% |
| Q4 25 | 25.7% | 3.6% | ||
| Q3 25 | 51.6% | 3.5% | ||
| Q2 25 | 26.9% | 5.2% | ||
| Q1 25 | 65.7% | 4.4% | ||
| Q4 24 | 51.4% | 5.1% | ||
| Q3 24 | 12.6% | 3.7% | ||
| Q2 24 | 17.2% | 5.1% | ||
| Q1 24 | 22.7% | 5.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.36× | — | ||
| Q1 24 | -15.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMS
| Direct Patient Services | $4.0M | 51% |
| Rental Income From Medical Services | $2.7M | 35% |
| Pbrt Services | $1.2M | 15% |
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
